Artificial nucleic acid molecules for improved protein expression

Patent metadata

Field	Value
Publication number	US-12442005-B2
Application number	US-202318330356-A
Country	US
Kind code	B2
Filing date	Jun 6, 2023
Priority date	Dec 12, 2014
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

The invention relates to a method for stimulating an immune response by intramuscular injection of an artificial nucleic acid molecule comprising an open reading frame encoding an antigen and a 3′-UTR comprising at least two poly(A) sequences. The method may yield an increased immune response to the antigen or an increased neutralizing antibody response to the antigen.

First claim

The invention claimed is:

1. A method for stimulating an immune response in an organism, the method comprising administering to the organism, by intramuscular injection, a RNA molecule comprising:
a) a 5′-cap structure;
b) at least one open reading frame (ORF) encoding an antigen; and
c) a heterologous 3′-untranslated region (3′-UTR) comprising at least a first and a second poly(A) sequence, wherein:
(i) the first poly(A) sequence comprises at least 20 adenine nucleotides; and
(ii) the second poly(A) sequence comprises at least 60 adenine nucleotides,

wherein the first and the second poly(A) sequences are separated by a linker nucleic acid sequence comprising at least 3 consecutive nucleotides that are not adenine nucleotides,
wherein when the RNA molecule is administered intramuscularly to the organism, the RNA molecule yields increased expression of the antigen encoded by the at least one open reading frame in comparison to the expression from a reference nucleic acid molecule comprising an identical nucleic acid sequence as the RNA molecule but lacking the linker nucleic acid sequence.

2. The method of claim 1 , wherein the second poly(A) sequence comprises at least 70 adenine nucleotides.

3. The method of claim 2 , wherein the heterologous 3′-UTR comprises, from 5′ to 3′, (i) the first poly(A) sequence; (ii) the linker nucleic acid sequence; and (iii) the second poly(A) sequence.

4. The method of claim 3 , wherein the second poly(A) sequence is located at the 3′ terminus of the RNA molecule.

5. The method of claim 4 , wherein the linker nucleic acid sequence comprises at least 5 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

6. The method of claim 5 , wherein the second poly(A) sequence comprises 100 adenine nucleotides.

7. The method of claim 5 , wherein the RNA molecule comprises a heterologous 5′ UTR sequence.

8. The method of claim 7 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

9. The method of claim 5 , wherein the RNA molecule is a bicistronic RNA.

10. The method of claim 5 , wherein the RNA molecule is a viral vector RNA.

11. The method of claim 5 , wherein the at least one ORF encoding the antigen has a G/C content that is increased by at least 15 percentage points relative to a corresponding reference ORF encoding the antigen.

12. The method of claim 5 , wherein the antigen is a tumor antigen.

13. The method of claim 5 , wherein the antigen is from a pathogen associated with an infectious disease.

14. The method of claim 13 , wherein the antigen is a viral antigen.

15. The method of claim 14 , wherein the viral antigen is from influenza virus, respiratory syncytial virus, herpes simplex virus, human papilloma virus, human immunodeficiency virus, dengue virus, cytomegalovirus, hepatitis B virus, rabies virus, coronavirus or yellow fever virus.

16. The method of claim 15 , wherein the viral antigen is an influenza virus antigen.

17. The method of claim 16 , wherein the influenza virus antigen is a HA antigen.

18. The method of claim 16 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

19. The method of claim 15 , wherein the viral antigen is a coronavirus antigen.

20. The method of claim 5 , wherein the RNA molecule is complexed with a cationic carrier or a polycationic carrier.

21. The method of claim 20 , wherein the cationic or the polycationic carrier comprises a cationic lipid.

22. The method of claim 21 , wherein the RNA molecule is transfected into cells of the organism in a nanoparticle.

23. The method of claim 22 , wherein when the RNA molecule is administered intramuscularly to the organism, the RNA molecule yields an increased immune response to the antigen encoded by the at least one open reading frame in comparison to an immune response generated by the reference nucleic acid molecule comprising the identical nucleic acid sequence as the RNA molecule but lacking the linker nucleic acid sequence.

24. The method of claim 23 , wherein when the RNA molecule is administered intramuscularly to the organism, the RNA molecule yields an increased neutralizing antibody response to the antigen encoded by the at least one open reading frame in comparison to a neutralizing antibody response generated by the reference nucleic acid molecule comprising the identical nucleic acid sequence as the RNA molecule but lacking the linker nucleic acid sequence.

25. The method of claim 22 , wherein the RNA molecule is a bicistronic RNA.

26. The method of claim 25 , wherein the antigen is an influenza virus HA antigen.

27. The method of claim 25 , wherein the antigen is a coronavirus antigen.

28. The method of claim 22 , wherein the RNA molecule is a viral vector RNA.

29. The method of claim 22 , wherein the RNA molecule comprises at least one nucleotide analog comprising a modified form of uridine chemically altered by methylation.

30. The method of claim 29 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence comprises at least 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

31. The method of claim 30 , wherein the antigen is an influenza virus HA antigen.

32. The method of claim 30 , wherein the antigen is a coronavirus antigen.

33. The method of claim 30 , wherein the first poly(A) sequence consists of 25 to 85 adenine nucleotides.

34. The method of claim 33 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

35. The method of claim 33 , wherein the at least one ORF is at least partially codon optimized.

36. The method of claim 33 , wherein the first poly(A) sequence consists of 30 adenine nucleotides.

37. The method of claim 36 , wherein the second poly(A) sequence consists of 70 adenine nucleotides.

38. The method of claim 21 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

39. The method of claim 5 , wherein the at least one ORF is at least partially codon optimized.

40. The method of claim 5 , wherein the first poly(A) sequence consists of 25 to 85 adenine nucleotides.

41. The method of claim 40 , wherein the second poly(A) sequence consists of 100 adenine nucleotides.

Assignees

• CureVac SE

Inventors

• Thess Andreas
• Schlake Thomas
• Grund Stefanie

Classifications

• C12N2830/50

  regulating RNA stability, not being an intron, e.g. poly A signal · CPC title

• C12N2760/20171

  Demonstrated in vivo effect · CPC title

• C12N2760/20134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/16171

  Demonstrated in vivo effect · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title